Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart.

BACKGROUND Advances in breast cancer (BC) research have demonstrated differences between black and white women with regarding tumour behaviour, patient outcome and response to treatment which can be explained by underlying genetic changes. The tumour suppressor gene p53 has been speculated to be involved in tumour biology of triple negative and/or basal -like BC and more commonly observed in black than caucasian women. MATERIALS AND METHODS In this study, the protein expression of p53 was investigated in tissue samples from a series of 308 Nigerian women, prepared as a tissue microarray (TMA), using immunohistochemistry. Clinicopathological parameters, biomarkers of functional significance in BC and patient outcome of tumours expressing p53 in Nigerian women were correlated with UK grade matched series. RESULTS A significantly large proportion of BC from Nigerian women showed high p53 expression compared with UK women (p<0.001). In those tumours showing positive p53 in the Nigerian series, a significant proportion were premenopausal, diagnosed before 50 years, larger in size, with evidence of metastasis into lymphatic vessels ( all p<0.001). In addition, p53 positive expression was also significantly correlated with negative expression of ER and PgR (p<0.001, p<0.03 respectively), BRCA1, MDM2 (all p<0.001), p21 (p=0.006) and E-cadherin (p=0.001) and positively associated with P-cadherin (p=0.001), triple negative phenotype, basal cytokeratin (CK) 5/6 expression (p<0.04) and basal phenotype compared with the UK series (p<0.001). Survival analyses showed Nigerian women with BC were significantly associated with poor BC specific survival (p<0.001, but no significant association with disease free interval was observed. CONCLUSION In this study, protein expressions of p53 pathways are different between Nigerian and UK BC women and this may also contribute to differences in tumour biology. Therefore, targeting these p53 pathways for therapeutic usage might improve the poor outcome observed in Black Nigerian women.

[1]  Mutsuko Ouchi,et al.  BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. , 2015, The Journal of Biological Chemistry.

[2]  Jochen H M Prehn,et al.  Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy , 2011, Gut.

[3]  Steffen Jung,et al.  CKIα ablation highlights a critical role for p53 in invasiveness control , 2011, Nature.

[4]  A. Børresen-Dale,et al.  BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations , 2010, BMC Cancer.

[5]  I. Ellis,et al.  The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers , 2010, The Journal of pathology.

[6]  I. Ellis,et al.  Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens , 2010, Histopathology.

[7]  Ayesha Ahmed,et al.  Protein expression profile and prevalence pattern of the molecular classes of breast cancer - a Saudi population based study , 2010, BMC Cancer.

[8]  C. Perou,et al.  Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Dewitty,et al.  Clinical Significance of p53 and bcl-2 Protein Coexpression Phenotypes in Molecular Breast Cancer Subtypes of Pre-menopausal and Post-menopausal African-American Women , 2009, The American surgeon.

[10]  I. Ellis,et al.  The Nottingham Prognostic Index for Invasive Carcinoma of the Breast , 2008, Pathology & Oncology Research.

[11]  Kimberly S. Chiew,et al.  Development and evaluation of a decision aid for patients considering first‐line chemotherapy for metastatic breast cancer , 2008, Health expectations : an international journal of public participation in health care and health policy.

[12]  Gema Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[13]  H. Yamashiro,et al.  Update of evidence in chemotherapy for breast cancer , 2008, International Journal of Clinical Oncology.

[14]  S. Dermime,et al.  Expression of B7‐H1 in breast cancer patients is strongly associated with high proliferative Ki‐67‐expressing tumor cells , 2007, International journal of cancer.

[15]  Fengzhi Li,et al.  Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. , 2007, Cancer research.

[16]  P. Lønning,et al.  Breast cancer prognostication and prediction in the postgenomic era. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Ian O Ellis,et al.  Prognostic markers in triple‐negative breast cancer , 2007, Cancer.

[18]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[19]  G. Hortobagyi,et al.  Overview of resistance to systemic therapy in patients with breast cancer. , 2007, Advances in experimental medicine and biology.

[20]  Douglas Macmillan,et al.  Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. , 2006, European journal of cancer.

[21]  Julie E Goodman,et al.  Association of breast cancer outcome with status of p53 and MDM2 SNP309. , 2006, Journal of the National Cancer Institute.

[22]  M. Dai,et al.  14‐3‐3γ binds to MDMX that is phosphorylated by UV‐activated Chk1, resulting in p53 activation , 2006, The EMBO journal.

[23]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B. Vojtesek,et al.  Discriminating functional and non‐functional p53 in human tumours by p53 and MDM2 immunohistochemistry , 2005, The Journal of pathology.

[25]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[26]  H. Hibshoosh,et al.  African‐American/White differences in breast carcinoma , 2005, Cancer.

[27]  R. Elledge,et al.  Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancer , 2005, Breast Cancer Research and Treatment.

[28]  S. Pinder,et al.  E‐cadherin expression in invasive non‐lobular carcinoma of the breast and its prognostic significance , 2005, Histopathology.

[29]  Petra de Graaf,et al.  Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Keith R. Johnson,et al.  Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition , 2005, Journal of Cell Science.

[31]  L. Attardi.  The role of p53-mediated apoptosis as a crucial anti-tumor response to genomic instability: lessons from mouse models. , 2005, Mutation research.

[32]  I. Ellis,et al.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma , 2004, British Journal of Cancer.

[33]  C. Howe,et al.  African‐American/White differences in breast carcinoma , 2004, Cancer.

[34]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[35]  Kristian Helin,et al.  Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity , 2004, Molecular and Cellular Biology.

[36]  R. Coates,et al.  Racial differences in the expression of cell cycle–regulatory proteins in breast carcinoma , 2004, Cancer.

[37]  F. B. Davis,et al.  Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells , 2004, British Journal of Cancer.

[38]  S. Ding,et al.  Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade , 2004, British Journal of Cancer.

[39]  G. Landberg,et al.  G1‐S transition defects occur in most breast cancers and predict outcome , 1999, Breast Cancer Research and Treatment.

[40]  R. Scolyer,et al.  Tumour Angiogenesis and p53 Protein Expression in Mammary Phyllodes Tumors , 2003, Modern Pathology.

[41]  S. Pinder,et al.  Loss of CD59 expression in breast tumours correlates with poor survival , 2003, The Journal of pathology.

[42]  Yang Xu,et al.  Regulation of p53 responses by post-translational modifications , 2003, Cell Death and Differentiation.

[43]  Isabelle Bedrosian,et al.  Cyclin E and survival in patients with breast cancer. , 2002, The New England journal of medicine.

[44]  Yolande F M Ramos,et al.  Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. , 2001, Cancer research.

[45]  Samuel H. Wilson,et al.  A role for p53 in base excision repair , 2001, The EMBO journal.

[46]  J. Bergh,et al.  A systematic overview of chemotherapy effects in breast cancer. , 2001, Acta oncologica.

[47]  M. Gnant,et al.  TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  D. George,et al.  Stabilization of the MDM2 Oncoprotein by Interaction with the Structurally Related MDMX Protein* , 1999, The Journal of Biological Chemistry.

[49]  K. Shirouzu,et al.  MDM2 interacts with MDMX through their RING finger domains , 1999, FEBS letters.

[50]  M. Wicha,et al.  Regulation of metastasis‐related gene expression by p53: A potential clinical implication , 1999, Molecular carcinogenesis.

[51]  A. Levine,et al.  Functions of the MDM2 oncoprotein , 1999, Cellular and Molecular Life Sciences CMLS.

[52]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[53]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[54]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[55]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[56]  James M. Roberts,et al.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.

[57]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[58]  P. Shaw,et al.  The role of p53 in cell cycle regulation. , 1996, Pathology, research and practice.

[59]  James Brugarolas,et al.  Radiation-induced cell cycle arrest compromised by p21 deficiency , 1995, Nature.

[60]  D. Carney,et al.  Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. , 1995, British Journal of Cancer.

[61]  S. Joslyn.  Racial differences in survival from breast cancer. , 1995, JAMA.

[62]  C K Redmond,et al.  Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. , 1994, JAMA.

[63]  G M Clark,et al.  Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. , 1994, Journal of the National Cancer Institute.

[64]  Stephen J. Elledge,et al.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest , 1994, Cell.